Lenvatinib-Transarterial Chemoembolization Sequential Therapy as an Effective Treatment at Progression during Lenvatinib Therapy for Advanced Hepatocellular Carcinoma
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
Lenvatinib-Transarterial Chemoembolization Sequential Therapy as an Effective Treatment at Progression during Lenvatinib Therapy for Advanced Hepatocellular Carcinoma ; volume:9 ; number:6 ; year:2020 ; pages:756-770
Liver cancer ; 9, Heft 6 (2020), 756-770
- Creator
-
Kawamura, Yusuke
Kobayashi, Masahiro
Shindoh, Junichi
Kobayashi, Yuta
Okubo, Satoshi
Tominaga, Licht
Kajiwara, Akira
Kasuya, Kayoko
Iritani, Soichi
Fujiyama, Shunichiro
Hosaka, Tetsuya
Saitoh, Satoshi
Sezaki, Hitomi
Akuta, Norio
Suzuki, Fumitaka
Suzuki, Yoshiyuki
Ikeda, Kenji
Arase, Yasuji
Hashimoto, Masaji
Kozuka, Tokuyo
Kumada, Hiromitsu
- DOI
-
10.1159/000510299
- URN
-
urn:nbn:de:101:1-2020120923292553981092
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:29 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Kawamura, Yusuke
- Kobayashi, Masahiro
- Shindoh, Junichi
- Kobayashi, Yuta
- Okubo, Satoshi
- Tominaga, Licht
- Kajiwara, Akira
- Kasuya, Kayoko
- Iritani, Soichi
- Fujiyama, Shunichiro
- Hosaka, Tetsuya
- Saitoh, Satoshi
- Sezaki, Hitomi
- Akuta, Norio
- Suzuki, Fumitaka
- Suzuki, Yoshiyuki
- Ikeda, Kenji
- Arase, Yasuji
- Hashimoto, Masaji
- Kozuka, Tokuyo
- Kumada, Hiromitsu
Other Objects (12)
Objective Response by mRECIST to Initial Lenvatinib Therapy Is an Independent Factor Contributing to Deep Response in Hepatocellular Carcinoma Treated with Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy
Transarterial chemoembolization combined with sintilimab and lenvatinib for the treatment of unresectable hepatocellular carcinoma: a retrospective study
Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study
Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study
Sorafenib versus lenvatinib-based sequential systemic therapy for advanced hepatocellular carcinoma: a real-world analysis
Transcatheter arterial chemoembolization plus Sorafenib versus transcatheter arterial chemoembolization plus Lenvatinib for intermediate hepatocellular carcinoma
Lenvatinib as a salvage therapy for advanced metastatic medullary thyroid cancer
Real Life Study of Lenvatinib Therapy for Hepatocellular Carcinoma: RELEVANT Study
A Phase 2, Prospective, Multicenter, Single-Arm Trial of Transarterial Chemoembolization Therapy in Combination Strategy with Lenvatinib in Patients with Unresectable Intermediate-Stage Hepatocellular Carcinoma: TACTICS-L Trial
Lenvatinib (Kisplyx) : Lenvatinib in Kombination mit Everolismus beim fortgeschrittenen Nierenzellkarzinom mit Hirnmetastasen
Lenvatinib plus pembrolizumab for systemic therapy-naïve and -experienced unresectable hepatocellular carcinoma
Lenvatinib with or without Concurrent Drug-Eluting Beads Transarterial Chemoembolization in Patients with Unresectable, Advanced Hepatocellular Carcinoma: A Real-World, Multicenter, Retrospective Study
Objective Response by mRECIST to Initial Lenvatinib Therapy Is an Independent Factor Contributing to Deep Response in Hepatocellular Carcinoma Treated with Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy
Transarterial chemoembolization combined with sintilimab and lenvatinib for the treatment of unresectable hepatocellular carcinoma: a retrospective study
Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study
Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study
Sorafenib versus lenvatinib-based sequential systemic therapy for advanced hepatocellular carcinoma: a real-world analysis
Transcatheter arterial chemoembolization plus Sorafenib versus transcatheter arterial chemoembolization plus Lenvatinib for intermediate hepatocellular carcinoma
Lenvatinib as a salvage therapy for advanced metastatic medullary thyroid cancer
Real Life Study of Lenvatinib Therapy for Hepatocellular Carcinoma: RELEVANT Study
A Phase 2, Prospective, Multicenter, Single-Arm Trial of Transarterial Chemoembolization Therapy in Combination Strategy with Lenvatinib in Patients with Unresectable Intermediate-Stage Hepatocellular Carcinoma: TACTICS-L Trial
Lenvatinib (Kisplyx) : Lenvatinib in Kombination mit Everolismus beim fortgeschrittenen Nierenzellkarzinom mit Hirnmetastasen
Lenvatinib plus pembrolizumab for systemic therapy-naïve and -experienced unresectable hepatocellular carcinoma
Lenvatinib with or without Concurrent Drug-Eluting Beads Transarterial Chemoembolization in Patients with Unresectable, Advanced Hepatocellular Carcinoma: A Real-World, Multicenter, Retrospective Study
Objective Response by mRECIST to Initial Lenvatinib Therapy Is an Independent Factor Contributing to Deep Response in Hepatocellular Carcinoma Treated with Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy
Transarterial chemoembolization combined with sintilimab and lenvatinib for the treatment of unresectable hepatocellular carcinoma: a retrospective study
Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study
Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study
Sorafenib versus lenvatinib-based sequential systemic therapy for advanced hepatocellular carcinoma: a real-world analysis
Transcatheter arterial chemoembolization plus Sorafenib versus transcatheter arterial chemoembolization plus Lenvatinib for intermediate hepatocellular carcinoma
Lenvatinib as a salvage therapy for advanced metastatic medullary thyroid cancer
Real Life Study of Lenvatinib Therapy for Hepatocellular Carcinoma: RELEVANT Study
A Phase 2, Prospective, Multicenter, Single-Arm Trial of Transarterial Chemoembolization Therapy in Combination Strategy with Lenvatinib in Patients with Unresectable Intermediate-Stage Hepatocellular Carcinoma: TACTICS-L Trial
Lenvatinib (Kisplyx) : Lenvatinib in Kombination mit Everolismus beim fortgeschrittenen Nierenzellkarzinom mit Hirnmetastasen
Lenvatinib plus pembrolizumab for systemic therapy-naïve and -experienced unresectable hepatocellular carcinoma